Global biotechnology company BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on Wednesday that it has named Greg Friberg, MD as its new executive vice president, chief research & development officer, effective 30 September.

In the new role, Dr Friberg will be responsible for the company's R&D organisation, including discovery research, preclinical, translational and clinical programs, and global regulatory and medical affairs.

Dr Friberg has more than two decades of industry experience. He has served at Amgen Inc for 18 years, most recently as vice president, Global Medical Affairs, Rare Disease.